At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jeremy S. Abramson, MD, of the Massachusetts General Hospital Cancer Center, Boston, MA, discusses a multicentre phase 2 study, which is evaluating brentuximab vedotin plus adriamycin, vinblastine and dacarbazine (AVD) for patients with non-bulky limited-stage Hodgkin lymphoma.
